Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)

NCT02495415 is registered in ClinicalTrials.gov with CerRx, Inc. as lead sponsor.

NCT NCT02495415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02495415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)
Lead sponsor
CerRx, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2016
Completion date
December 31, 2021
Enrollment
140 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma